Cargando…
PD-L1 Expressing Recurrent Clear Cell Carcinoma of the Vulva with Durable Partial Response to Pembrolizumab: A Case Report
BACKGROUND: The optimal treatment and molecular landscape of recurrent clear cell carcinoma of the vulva (VCCC) are unknown. No reported data exist regarding the efficacy of anti-programmed death 1 (PD-1) immune checkpoint inhibition in VCCC. We report on a patient with chemotherapy-refractory recur...
Autores principales: | Sachdeva, Manavi, Ngoi, Natalie Y L, Lim, Diana, Poon, Michelle L M, Thian, Yee Liang, Lim, Yi Wan, Lim, Siew Eng, Tong, Pearl, Lum, Jeffrey H Y, Ng, Joseph, Ilancheran, Arunachalam, Domingo, Efren J, Low, Jeffrey J H, Tan, David S P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254584/ https://www.ncbi.nlm.nih.gov/pubmed/34234460 http://dx.doi.org/10.2147/OTT.S309661 |
Ejemplares similares
-
Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer
por: Ngoi, N.Y.L., et al.
Publicado: (2018) -
A complete durable response of vaginal clear cell carcinoma with pembrolizumab: A case report
por: Porragas-Paseiro, Hector S., et al.
Publicado: (2023) -
Pembrolizumab in FIGO IVB Verrucous Carcinoma of the Vulva: A Case Report
por: Wang, Yuhan, et al.
Publicado: (2021) -
Primary clear cell carcinoma of the vulva: A case report
por: Pomerantz, Tali, et al.
Publicado: (2023) -
Does external beam radiation boost to pelvic lymph nodes improve outcomes in patients with locally advanced cervical cancer?
por: Wujanto, Caryn, et al.
Publicado: (2019)